NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease
NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease
NKGen Biotech宣佈其安全審查委員會已批准Co.s SNK01 將進入阿爾茨海默氏病的第二階段開發
NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease
NKGen Biotech宣佈其安全審查委員會已批准Co.s SNK01 將進入阿爾茨海默氏病的第二階段開發
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。